CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD)
Authors
O Cappellari
G Dickson
+7 more
L Forrest
P Harish
N Lu-Nguyen
A Malerba
L Popplewell
F Roth
C Trollet
Publication date
7 May 2019
Publisher
'Wiley'
Doi
Abstract
Copyright © 2019 The Authors. Background: Oculopharyngeal muscular dystrophy (OPMD) is a late-onset muscle disease affecting one per 80 000 of the general population characterized by profound dysphagia and ptosis, and limb weakness at later stages. Affected muscles are characterized by increased fibrosis and atrophy. Myostatin is a negative regulator of muscle mass, and inhibition of myostatin has been demonstrated to ameliorate symptoms in dystrophic muscles. Methods: In this study, we performed a systemic delivery of a monoclonal antibody to immunologically block myostatin in the A17 mouse model of OPMD. The mice were administered a weekly dose of 10 mg/kg RK35 intraperitonially for 10 weeks, following which histological analyses were performed on the samples. Results: This treatment significantly (P < 0.01) improved body mass (11%) and muscle mass (for the tibialis anterior and extensor digitorum longus by 19% and 41%) in the A17 mice treated with RK35 when compared to saline controls. Similarly, a significantly (P < 0.01) increased muscle strength (18% increase in maximal tetanic force) and myofibre diameter (17% and 44% for the tibialis anterior and extensor digitorum longus), and reduced expression of markers of muscle fibrosis (40% reduction in area of expression), was also observed. No change in the density of intranuclear inclusions (a hallmark of disease progression of OPMD) was however observed. Conclusions: Our study supports the clinical translation of such antibody-mediated inhibition of myostatin as a treatment of OPMD. This strategy has implications to be used as adjuvant therapies with gene therapy based approaches, or to stabilize the muscle prior to myoblast transplantation
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
HAL Descartes
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:HAL:hal-02466979v1
Last time updated on 17/02/2020
RVC Research Online
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:researchonline.rvc.ac.uk:1...
Last time updated on 15/05/2019
Archive Ouverte en Sciences de l'Information et de la Communication
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:HAL:hal-02466979v1
Last time updated on 26/02/2020
Sustaining member
Brunel University Research Archive
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:bura.brunel.ac.uk:2438/241...
Last time updated on 21/02/2022
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 31/10/2020